ALOPM — Oncodesign Precision Medicine Opm SA Balance Sheet
0.000.00%
Last trade - 00:00- €12.88m
- €16.95m
- €0.21m
- 28
- 77
- 71
- 63
Annual balance sheet for Oncodesign Precision Medicine Opm SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | FAS | FAS | FAS | FAS | FAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 8.43 | 4.92 | 13.4 | 10.3 | 5.27 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.59 | 1.55 | 2.89 | 3.74 | 2.93 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 11.2 | 6.54 | 16.4 | 14.4 | 8.66 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.156 | 0.932 | 0.896 | 0.76 | 0.633 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 12.4 | 8.37 | 18.4 | 16.6 | 10.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.81 | 2.03 | 4.55 | 5.68 | 10.4 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.44 | 4.17 | 6.59 | 12.9 | 11.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 6.97 | 4.2 | 11.8 | 3.69 | -0.429 |
| Total Liabilities & Shareholders' Equity | 12.4 | 8.37 | 18.4 | 16.6 | 10.7 |
| Total Common Shares Outstanding |